

Clinical trials of antithrombotics for acute coronary syndrome in patients with a recent ACS

TrialResults-center www.trialresultscenter.org

1 oral factor Xa inhibitor

Trial	Treatments	Patients	Trials design and methods
apixaban vs placebo			
APPRAISE 2 , 2011 [NCT00831441] n=3705/3687 follow-up: 8 months	apixaban 5mg twice daily versus placebo	patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events	Parallel groups double blind 39 countries
APPRAISE-1 (10mg od) , 2009 [NCT00313300] n=318/611 follow-up: 6 months	apixaban 10 mg once daily versus placebo	patients with a recent ST-elevation or nonST-elevation acute coronary syndrome(<7 days)	Parallel groups double blind Europe, Middle East, North America
APPRAISE-1 (2.5 mg bid) , 2009 [NCT00313300] n=NA follow-up: 6 months	Apixaban 2.5mg twice daily versus placebo	patients with a recent ST-elevation or nonST-elevation acute coronary syndrome(<7 days)	double blind Europe, Middle East, North America
APPRAISE japan ongoing [NCT00852397] n=NA follow-up:	2 doses of apixaban (2.5 mg BID and 5.0 mg BID) for 24 weeks in combination with standard therapy (aspirin and /or additional antiplatelet therapy) versus placebo	patients with recent (<=7 days) acute coronary syndrome	double-blind Japan
rivaroxaban 2.5mg vs placebo			
ATLAS ACS 2 - TIMI 51 (2.5mg) , 2011 [NCT00809965] n=5174/5176 follow-up: 13 months	rivaroxaban 2.5 mg twice daily in addition to standard care versus placebo	patients with a recent ACS	Parallel groups double blind 44 countries
rivaroxaban 5mg vs placebo			
ATLAS ACS 2 - TIMI 51 (5mg) , 2011 [NCT00809965] n=5176/5176 follow-up: 13 months	rivaroxaban 5 mg twice daily in addition to standard care versus placebo	patients with a recent ACS	double blind 44 countries
ximelagatran vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
ESTEEM , 2003 n=1245/638 follow-up: 6 months	oral ximelagatran at doses of 24 mg, 36 mg, 48 mg, or 60 mg twice daily versus placebo	patients who had had recent ST-elevation or non-STelevation myocardial infarction	Parallel groups double-blind

References

APPRAISE 2, 2011:

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011 Jul 24;: [21780946] [10.1056/NEJMoa1105819](https://doi.org/10.1056/NEJMoa1105819)

APPRAISE-1 (10mg od), 2009:

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 2009;: [19470889]

APPRAISE-1 (2.5 mg bid), 2009:

APPRAISE japan, :

ATLAS ACS 2 - TIMI 51 (2.5mg), 2011:

ATLAS ACS 2 - TIMI 51 (5mg), 2011:

ESTEEM, 2003:

2

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.